search
Back to results

His-bundle Pacing vs. Right Ventricular Apical Pacing in Patients With Reduced Ejection Fraction (HIS-PrEF)

Primary Purpose

His Bundle Pacing, Heart Failure, Systolic

Status
Recruiting
Phase
Not Applicable
Locations
Sweden
Study Type
Interventional
Intervention
His-bundle pacing
Sponsored by
Region Skane
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for His Bundle Pacing focused on measuring His bundle pacing, Conduction system pacing, Heart failure, systolic, Quality of life, Left ventricular ejection fraction

Eligibility Criteria

18 Years - 100 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • AV block II or III with high expected pacing need
  • Left ventricular ejection fraction between 40% and 55% (inclusive)
  • Willing to participate and sign informed consent

Exclusion Criteria:

  • Under 18 years old
  • Pregnant
  • Hypertrophic cardiomyopathy
  • Cardiac sarcoidosis
  • Cardiac amyloidosis
  • Previous myocardial infarction within last 3 months
  • Ventricular septum defect or other other left ventricular corrective surgery
  • Congenital heart disease surgically corrected
  • Atrial fibrillation with uncontrolled rate (if not planned for AV node ablation)

Sites / Locations

  • Skane University HospitalRecruiting
  • Norrland University HospitalRecruiting
  • Region Hallands Sjukhus VarbergRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

His-bundle pacing first

RV apical pacing first

Arm Description

Patients are allocated to receive His-bundle pacing for a period of 6 months. Then the patients will cross over to traditional right ventricular (RV) apical pacing for 6 months.

Patients are allocated to receive traditional RV apical pacing for a period of 6 months. Then the patients will cross over to His-bundle pacing for 6 months.

Outcomes

Primary Outcome Measures

Ejection Fraction
Absolute difference in left ventricular systolic ejection fraction (absolute percent)

Secondary Outcome Measures

Adverse events
Percentage of device-related adverse events. Events will be classified as general, associated with His-bundle lead or associated with RV lead
Left ventricular activation time
Total left ventricular mechanical activation time (measured with tissue doppler echocardiography)
NT-ProBNP
Difference in NT-ProBNP levels
QRS duration
Difference in total QRS duration on ECG
Left Ventricular Activation Time (LVAT)
Maximum unipolar spike-to-peak-T-wave in V5-V6
6 minute walk test
Difference in six minute hall walk test (meters)
Change in quality of life measured by the Short Form Health Survey (SF-36) mean score
Difference in health related quality of life, measured by the SF-36 questionnaire, calculated as difference in mean from baseline to follow-up (calculated using the official scoring algorithm, where each sub scale is assigned a score between 0-100, higher score represents better health)
Change in quality of life measured by the EuroQol EQ-5D-5L Questionnaire
Difference in health related quality of life, measured by the mean score of the EQ-5D (version 5L) questionnaire (totalt score ranging from 5-25 points, higher score represents more health related problems/disability)

Full Information

First Posted
August 24, 2020
Last Updated
February 16, 2023
Sponsor
Region Skane
search

1. Study Identification

Unique Protocol Identification Number
NCT04529577
Brief Title
His-bundle Pacing vs. Right Ventricular Apical Pacing in Patients With Reduced Ejection Fraction
Acronym
HIS-PrEF
Official Title
His-bundle Pacing vs. Right Ventricular Apical Pacing in Patients With Reduced Ejection
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
December 1, 2020 (Actual)
Primary Completion Date
December 2024 (Anticipated)
Study Completion Date
December 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Region Skane

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The study compares standard right ventricle apical pacing with so called His-bundle pacing, for patients with slightly or moderately reduced ejection fraction and atrioventricular block requiring pacemaker therapy. The primary outcome is left ventricular ejection fraction measured after 6 months.
Detailed Description
Patients with reduced systolic ejection fraction (40≤ ejection fraction ≤55%) and pacemaker indication due to high degree AV block are included. The study has a randomized double blinded crossover design. Patients are implanted with a standard right ventricle lead and right atrial lead (if indicated), and in addition a His-bundle lead. Randomization is performed as to which pacing modality is used during the first 6 months. After 6 months the pacing modality is changed. Patients are blinded and endpoint adjudicators, including echocardiography staff, are blinded. Device nurse and physician are not blinded. Primary endpoint is difference in left ventricular ejection fraction after 6 months, paired comparisons are used and each patient is their own control. Secondary endpoints include complications and safety of the device/electrode, and quality of life.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
His Bundle Pacing, Heart Failure, Systolic
Keywords
His bundle pacing, Conduction system pacing, Heart failure, systolic, Quality of life, Left ventricular ejection fraction

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
Randomized double blinded crossover design.
Masking
ParticipantCare ProviderOutcomes Assessor
Masking Description
Patients and outcomes assessors are blinded. Staff involved in device programming are not blinded.
Allocation
Randomized
Enrollment
40 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
His-bundle pacing first
Arm Type
Experimental
Arm Description
Patients are allocated to receive His-bundle pacing for a period of 6 months. Then the patients will cross over to traditional right ventricular (RV) apical pacing for 6 months.
Arm Title
RV apical pacing first
Arm Type
Experimental
Arm Description
Patients are allocated to receive traditional RV apical pacing for a period of 6 months. Then the patients will cross over to His-bundle pacing for 6 months.
Intervention Type
Device
Intervention Name(s)
His-bundle pacing
Intervention Description
A standard pacing electrode (Medtronic 4076) will be placed in RV apex (or RV septum as a secondary option) and in the right atrial appendage (if indicated). A dedicated His-bundle pacemaker electrode (Medtronic 3830) will be placed in the region of His bundle, using a dedicated introducer sheath (Medtronic C304 or Medtronic C315). His-bundle potentials will be identified and His-bundle capture (non-selective or selective) will be ascertained using an electrophysiology recording system. Device programming will focus on providing physiological atrioventricular delay and safety RV pacing as backup.
Primary Outcome Measure Information:
Title
Ejection Fraction
Description
Absolute difference in left ventricular systolic ejection fraction (absolute percent)
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Adverse events
Description
Percentage of device-related adverse events. Events will be classified as general, associated with His-bundle lead or associated with RV lead
Time Frame
12 months
Title
Left ventricular activation time
Description
Total left ventricular mechanical activation time (measured with tissue doppler echocardiography)
Time Frame
6 months
Title
NT-ProBNP
Description
Difference in NT-ProBNP levels
Time Frame
6 months
Title
QRS duration
Description
Difference in total QRS duration on ECG
Time Frame
6 months
Title
Left Ventricular Activation Time (LVAT)
Description
Maximum unipolar spike-to-peak-T-wave in V5-V6
Time Frame
6 months
Title
6 minute walk test
Description
Difference in six minute hall walk test (meters)
Time Frame
6 months
Title
Change in quality of life measured by the Short Form Health Survey (SF-36) mean score
Description
Difference in health related quality of life, measured by the SF-36 questionnaire, calculated as difference in mean from baseline to follow-up (calculated using the official scoring algorithm, where each sub scale is assigned a score between 0-100, higher score represents better health)
Time Frame
6 months
Title
Change in quality of life measured by the EuroQol EQ-5D-5L Questionnaire
Description
Difference in health related quality of life, measured by the mean score of the EQ-5D (version 5L) questionnaire (totalt score ranging from 5-25 points, higher score represents more health related problems/disability)
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
100 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: AV block II or III with high expected pacing need Left ventricular ejection fraction between 40% and 55% (inclusive) Willing to participate and sign informed consent Exclusion Criteria: Under 18 years old Pregnant Hypertrophic cardiomyopathy Cardiac sarcoidosis Cardiac amyloidosis Previous myocardial infarction within last 3 months Ventricular septum defect or other other left ventricular corrective surgery Congenital heart disease surgically corrected Atrial fibrillation with uncontrolled rate (if not planned for AV node ablation)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Maiwand Farouq, MD, PhD
Phone
+ 46 40 336415‬
Email
maiwand.farouq@skane.se
First Name & Middle Initial & Last Name or Official Title & Degree
Rasmus Borgquist, MD
Phone
+46 46 171010
Email
rasmus.borgquist@med.lu.se
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Rasmus Borgquist, MD PhD
Organizational Affiliation
Lund University, Skane University Hospital, Arrhythmia Section, Lund, Sweden
Official's Role
Principal Investigator
Facility Information:
Facility Name
Skane University Hospital
City
Lund
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rasmus Borgquist
Phone
+4646171000
Email
rasmus.borgquist@med.lu.se
Facility Name
Norrland University Hospital
City
Umeå
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Steen Jensen, MD PhD
Email
steen.jensen@medicin.umu.se
Facility Name
Region Hallands Sjukhus Varberg
City
Varberg
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Cecilia Rorsman
Email
Cecilia.Rorsman@regionhalland.se

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

His-bundle Pacing vs. Right Ventricular Apical Pacing in Patients With Reduced Ejection Fraction

We'll reach out to this number within 24 hrs